A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification

A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification

IntroductionGastric cancer is a highly heterogeneous malignant tumor of the digestive system. Anti-HER2 treatment can inhibit downstream signaling pathways and improve clinical treatment and outcomes in patients with HER2 protein overexpression. Currently, two standard methods for evaluating HER2 ex...

Full description

Bibliographic Details
Main Authors:	Bin Xu, Hui Chen, Jingjing Zhang, Yanghai Cong, Li Ning, Limin Chen, Yushi Zhang, Yong Zhang, Zhanchun Song, Yuan Meng, Lianqi He, Wei-li Liao, Ying Lu, Fengyi Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Oncology
Subjects:	gastric cancer mixed classification HER2 IHC MS-SRM types identification
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1152895/full

Similar Items

HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas
by: Indu Rajagopal, et al.
Published: (2015-03-01)

Diagnostic value of IHC and FISH methods for HER2 gene amplification detection in paraffin embedded blocks of breast cancer
by: Seyed Ahmad Aleyasin, et al.
Published: (2023-01-01)

The Study of HER-2/neu, ER/PR Expression Using Immunohistochemistry (IHC) in the Iraqi Breast Cancer
by: Suhad Faisal Hatem, et al.
Published: (2016-06-01)

Association between HER-2/Neu overexpression in gastric adenocarcinoma and histopathologic features of tumor in gastrectomy samples: a cross-sectional study in Kerman, Iran
by: Mohammad Mahdi Hayatbakhsh Abbasi, et al.
Published: (2019-05-01)

The Discordance Between HER-2/NEU Expression Assessed by Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH): Is It Important to Detect?
by: Berna Bozkurt Duman, et al.
Published: (2014-02-01)

Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial
by: Zhou Fei, et al.
Published: (2012-12-01)

Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
by: Eliya Farah, et al.
Published: (2024-01-01)

HER2 overexpression is a putative diagnostic and prognostic biomarker for late-stage colorectal cancer in North African patients
by: Eman A. Abdul Razzaq, et al.
Published: (2021-01-01)

Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma
by: Miladinović Mirjana, et al.
Published: (2021-10-01)

Analysis of the IHC Adaptation for the Anthropomorphic Speech Processing Systems
by: Petrovsky Alexander A, et al.
Published: (2005-01-01)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
by: Fanfan Li, et al.
Published: (2022-03-01)

HER2 (ERBB2) alterations in colorectal cancers
by: Nika Tavberidze, et al.
Published: (2022-06-01)

Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients
by: Joseph Kattan, et al.
Published: (2022-11-01)

c-MET positivity and its relationship with histopathological findings in gastric carcinomas exhibiting HER2 gene expression
by: Ferhat Coskun, et al.
Published: (2022-01-01)

HER-2/NEU Ekspresyonun Saptanmasinda İmmunohistokimyasal ve Fish Yöntemi Arasında Diskordansin Belirlenmesi Önemli midir?
by: Berna Bozkurt DUMAN, et al.
Published: (2014-07-01)

Immunohistochemical HER2 Recognition and Analysis of Breast Cancer Based on Deep Learning
by: Yuxuan Che, et al.
Published: (2023-01-01)

A Study of Epidermal Growth Factor Receptor 2 (HER2/neu) Expression in Endoscopic Biopsies and Gastrectomy Specimens of Gastric Adenocarcinomas
by: Sheela Devi CS, et al.
Published: (2016-10-01)

Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication
by: Manuela Costantini, et al.
Published: (2020-11-01)

EVALUATION OF ALTERED PTEN EXPRESSION BY IHC AS A DIAGNOSTIC MARKER IN HYPERPLASTIC AND NEOPLASTIC ENDOMETRIUM OBSERVATIONAL DESCRIPTIVE STUDY.
by: Bodhisatwa Behera, et al.
Published: (2023-06-01)

Potential impact of HercepTest™ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis
by: Andrzej Marszałek, et al.
Published: (2023-07-01)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
by: Julie Sigrand, et al.
Published: (2016-03-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Immunohistochemistry (IHC) staining of in-vitro cancer cell-generated tumoroids
by: Meitham Amereh, et al.
Published: (2023-01-01)

Standardization and optimization of fluorescence in situ hybridization (FISH) for HER-2 assessment in breast cancer: A single center experience
by: Magdalena Bogdanovska-Todorovska, et al.
Published: (2018-05-01)

Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma
by: Döndü Nergiz, et al.
Published: (2022-01-01)

Using Whole Slide Gray Value Map to Predict HER2 Expression and FISH Status in Breast Cancer
by: Qian Yao, et al.
Published: (2022-12-01)

Gastrointestinal stromal tumors (GISTs) - IHC study and correlation of CD-117 and PDGFR-α staining intensity with histomorphological features - A study of 8 cases
by: L Krishna, et al.
Published: (2014-01-01)

Guest Editorial Foreword to the Special Issue of IHC 2018
by: Raquel O. Prates, et al.
Published: (2019-12-01)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
by: Didi Feldman, et al.
Published: (2023-10-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
by: Hongsik Kim, et al.
Published: (2019-09-01)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
by: Diana B. Peckys, et al.
Published: (2021-11-01)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
by: Maluki Radford, et al.
Published: (2023-08-01)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
by: Sun J, et al.
Published: (2022-07-01)

Hacia un sistema de software basado en ihc para el apoyo de niños con capacidades auditivas diferentes
by: Gerardo Cruz González, et al.
Published: (2020-10-01)

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
by: Chun-wei Xu, et al.
Published: (2018-04-01)

A Deep Learning Quantification Algorithm for HER2 Scoring of Gastric Cancer
by: Zixin Han, et al.
Published: (2022-05-01)

Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis
by: X. Zhang, et al.
Published: (2018-01-01)

HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
by: N S Besova
Published: (2014-09-01)

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
by: Weiling Li, et al.
Published: (2022-09-01)